NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME FOR THE TREATMENT OF CANCER

The present invention pertains to antigen binding proteins (ABP) which bind to Transforming Growth Factor β Receptor 2 (TGFβR2) derived antigenic peptides. The invention in particular provides novel ABPs, such as T cell receptor (TCR) based molecules, which are selective and specific for an antigeni...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PONCETTE, Lucia, BLANKENSTEIN, Thomas, PLEWA, Natalia
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention pertains to antigen binding proteins (ABP) which bind to Transforming Growth Factor β Receptor 2 (TGFβR2) derived antigenic peptides. The invention in particular provides novel ABPs, such as T cell receptor (TCR) based molecules, which are selective and specific for an antigenic peptide derived from a frameshift variant of TGFβR2. The TCR of the invention, and ABPs derived therefrom, are of use for the treatment of a proliferative disorder, such as a cancer positive for the expression of TGFβR2 frameshift peptide. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing antigen binding proteins and pharmaceutical compositions comprising the compounds of the invention.